TiGenix, S.A.U.; S.A.U.;TiGenix;Consejo Superior de Investigaciones Cientificas
发明人:
BUSCHER Dirk,GONZALEZ DE LA PENA Manuel Angel,DELGADO MORA Mario
申请号：
SI200632094
公开号：
SI1926813T1
申请日:
2006.09.22
申请国别(地区):
SI
年份:
2016
代理人:
摘要：
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-³) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
